Cite
HARVARD Citation
Morton, G. et al. (2020). Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy. Radiotherapy and oncology. pp. 90-96. [Online].